← Dogwood Therapeutics, Inc. (DWTX) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Dogwood Therapeutics, Inc. (DWTX)
Pharmaceutical Preparations · market cap $51M · as of 2026-07-16
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-10-31
Phase 2
Pipeline
1
programs
Upcoming events
2
next 90d+
Dossier
Ready
cached
Dogwood Therapeutics (DWTX) is a micro-cap clinical-stage pharmaceutical company with a market cap of ~$48M and 12 employees, focused on a single lead asset, Halneuron, currently in Phase 2 development for chemotherapy-induced neuropathic pain (CINP). The company carries $13.2M in cash against a burn rate implying roughly 8.7 months of runway, with no revenue and an accelerating net loss trajectory — $34M net loss in 2025 versus $12M in 2024.
The catalyst path
- 2026-10-31Phase 2imp 6/10
- 2026-11-05 (est.)Earningsimp 5/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Halneuron | Phase 2 | Chemotherapy Induced Neuropathic Pain |
Price & technical context
3-month
+9.4%
6-month
-28.4%
12-month
-78.6%
52-wk range
$1.34–$6.82
vs 50-day MA
-20.8%
vs 200-day MA
-33.7%
Realized vol
90.8%
Max drawdown
-92.3%
Daily closes through 2026-10-02. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for DWTX (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 1 registered trial on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.